Compare GSK plc (GSK) vs Atlassian Corporation PLC (TEAM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
GSK plc vs Atlassian Corporation PLC — how do they compare? GSK plc trades at $50.2 (market cap $102.60B), while Atlassian Corporation PLC trades at $152.2 (market cap $39.10B). The key difference: GSK plc is far larger — about 2.6× Atlassian Corporation PLC's market cap, and GSK plc pays a 3.57% dividend while Atlassian Corporation PLC pays none. Which is the better fit depends on your goals.
| GSK | TEAM | |
|---|---|---|
Market Cap | $102.60B | $39.10B |
Sector | Health | Technology |
52-Week High | $61.18 | $182.36 |
52-Week Low | $38.22 | $57.15 |
Enterprise Value | $123.04B | $39.09B |
Dividend Yield | 3.57% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
GSK trades at $52.16, down 1.51% today, with a bullish technical signal supported by moving averages. The company reported strong Q2 2026 earnings of $1.36 per share, beating estimates, and announced a $2.52 billion cost-saving plan to accelerate drug development. Revenue growth remains steady, with 2025 revenue at $32.67 billion and net income of $5.72 billion, though profit margins have fluctuated in recent years.
Outlook is positive with continued earnings beats and strategic investments, but risks include competitive pressures and regulatory uncertainties. Analyst sentiment is mixed with 31% buy ratings, 55% hold, and 14% sell, reflecting cautious optimism amid execution risks and market volatility.
Atlassian (TEAM) stock trades at $151.87, up 1.88% today and near its 52-week high, reflecting strong momentum after a 35% surge post-Q4 earnings. The company reported 28% revenue growth to $1.77 billion, beating estimates, with cloud revenue accelerating to 31%. Technical indicators show bullish moving averages but overbought RSI levels, while fundamentals highlight robust growth amid negative net margins. Analyst sentiment is overwhelmingly positive, with 67% buy ratings and a $161.93 consensus target.
Outlook remains favorable driven by enterprise deal expansion and AI platform adoption, though risks include high valuation multiples (P/S 6.1, EV/EBITDA 184.26) and persistent net losses. Investors should weigh growth prospects against profitability challenges and market volatility. The stock's proximity to all-time highs suggests cautious optimism is warranted.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About GSK plc
In the pharmaceutical industry, GSK ranks as one of the largest firms by total sales. The company wields its might across several therapeutic classes, including respiratory, cancer, and antiviral, as well as vaccines. GSK uses joint ventures to gain additional scale in certain markets like HIV.
Read more on GSK →About Atlassian Corporation PLC
Atlassian produces software that helps teams work together more efficiently and effectively. The company provides project planning and management software, collaboration tools, and IT help desk solutions. The company operates in four segments: subscriptions (term licenses and cloud agreements), maintenance (annual maintenance contracts that provide support and periodic updates and are generally attached to perpetual license sales), perpetual license (upfront sale for indefinite usage of the software), and other (training, strategic consulting, and revenue from the Atlassian Marketplace app store). Atlassian was founded in 2002 and is headquartered in Sydney.
Read more on TEAM →
